Growth Metrics

Aurinia Pharmaceuticals (AUPH) Assets Average (2021 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Assets Average for 5 consecutive years, with $515.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Assets Average fell 3.99% year-over-year to $515.0 million, compared with a TTM value of $515.0 million through Sep 2025, down 3.99%, and an annual FY2024 reading of $549.4 million, up 7.83% over the prior year.
  • Assets Average was $515.0 million for Q3 2025 at Aurinia Pharmaceuticals, up from $503.7 million in the prior quarter.
  • Across five years, Assets Average topped out at $552.0 million in Q3 2023 and bottomed at $373.2 million in Q3 2021.
  • Average Assets Average over 5 years is $502.7 million, with a median of $515.0 million recorded in 2025.
  • The sharpest move saw Assets Average soared 30.03% in 2022, then dropped 3.99% in 2025.
  • Year by year, Assets Average stood at $451.7 million in 2021, then rose by 6.17% to $479.6 million in 2022, then rose by 15.01% to $551.5 million in 2023, then decreased by 0.28% to $550.0 million in 2024, then dropped by 6.36% to $515.0 million in 2025.
  • Business Quant data shows Assets Average for AUPH at $515.0 million in Q3 2025, $503.7 million in Q2 2025, and $527.7 million in Q1 2025.